FDA grants Bayer HealthCare Pharmaceuticals orphan drug designation for investigational Ciprofloxacin dry powder inhaler for the treatment of Cystic Fibrosis

WAYNE, N.J. - Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI...

read more

Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron® depot for the palliative treatment of advanced prostate cancer

ABBOTT PARK, Illinois — The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolid...

read more

Roche diagnostics purchases microarray instrument and accessory assets from BioMicro Systems

MADISON, USA - Roche Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) has purchased assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow. These assets consist ...

read more

Genentech provides update on phase III study of Avastin in men with late stage prostate cancer

SOUTH SAN FRANCISCO, Calif. - Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer a...

read more

Novartis covets the rest of Alcon, drugmaker offers $39.3 billion for huge chunk of eye-care firm

Novartis aims to buy the rest of leading eye-care firm Alcon for $39.3 billion U.S. to reduce reliance on prescription drugs, but is offering minority shareholders a worse deal than major owner Nestlé...

read more

Request for re-examination of ceftobiprole submitted to CHMP

BASEL, Switzerland - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces that the Applicant Janssen-Cilag International NV (Janssen-Cilag), a Johnson & Johnson company, has submitted a request for re-exam...

read more

Genzyme doesn’t give chief a bonus

Genzyme Corp.’s embattled chief executive, Henri A. Termeer, did not receive a bonus last year because of production problems at the company’s Allston Landing plant.

read more

Sigma-Aldrich licenses RAFT polymerization technology from CSIRO

ST. LOUIS - Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) ...

read more

Abbott receives U.S. FDA approval for new cataract multifocal intraocular lens

DES PLAINES, Illinois — Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for the TECNIS® Multifocal 1-Piece intraocular lens (IOL) for cataract patie...

read more

BINDER innovation prize for Anne Spang

Anne Spang will be presented with the BINDER Innovation Prize at the Annual Meeting of the Society for Cell Biology (DGZ), on 10th March, 2010. The scientist has been awarded the prize for her outstan...

read more

Santhera reports strong 2009 revenues of CHF 22.3m and is financed beyond 2011

LIESTAL, Switzerland - Santhera Pharmaceuticals (SIX: SANN) announced today the financial results for 2009 and updated on the development pipeline.

read more

Actelion announces Full year 2009 financial results

ALLSCHWIL/BASEL, Switzerland - Actelion Ltd (SIX: ATLN) today announced its financial results for the full year 2009. With total net revenues CHF1,772.6 million (FY 2008: CHF 1,473.5 m) and operating ...

read more

Clariant slashes hundreds of jobs in Switzerland

The Clariant specialty chemicals group announced a loss for 2009 on Tuesday and said it would cut 500 jobs, 400 of them in Switzerland.

read more

Novartis oral multiple sclerosis development compound Gilenia (FTY720) granted US priority review status

BASEL, Switzerland - Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009...

read more

Galapagos and MorphoSys expand antibody alliance

MECHELEN, Belgium and MARTINSRIED/MUNICH, Germany - Galapagos NV (Euronext: GLPG) and MorphoSys AG (FSE: MOR) announce that they have expanded their antibody alliance in bone & joint diseases.

read more

Roche collaborates with Merck on developmental test for cancer-related gene mutation

PLEASANTON, Calif - Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Mer...

read more

RIKEN Center for Genomics Medicine chooses Genedata Expressionist for high throughput proteomics R&D

BASEL, Switzerland and TOKJO, Japan - Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the Japanese research foundation RI...

read more

New Novartis CEO targets vaccines, generics buys

BASEL, Switzerland (Reuters) - Joe Jimenez, the new chief executive of Swiss drugmaker Novartis (NOVN.VX), is targeting bolt-on acquisitions as the group digests the multibillion dollar acquisition of...

read more

Basilea strikes licensing deal with Astellas

ZURICH - Swiss biotech Basilea struck a licensing deal with Japan's Astellas Pharma, bringing in an upfront payment of 75 million Swiss francs ($70 million) to help ease its cash shortage.

read more

Polyphor discovers a new class of antibiotics with a novel mode of action

ALLSCHWIL, Switzerland - Today, Polyphor Ltd published the discovery of a new class of antibiotics with a novel mode of action (Science, VOL 327, ISSUE 5968). This proprietary new class of antibiotics...

read more